Taysha Gene Therapies Inc to Discuss Astellas Pharma's Strategic InvestmentCall Transcript
Welcome to Taysha Gene Therapy Strategic Investment Conference Call. (Operator Instructions) Following management's prepared remarks, we will hold a brief question-and-answer session. As a reminder, this call is being recorded today, Tuesday, October 25, 2022.
I will now turn the call over to Dr. Kimberly Lee, Chief Corporate Affairs Officer. Please go ahead.
Good morning, and welcome to Taysha's Strategic Investment Conference Call. Joining me on today's call are RA Session II, Taysha's President, Founder and CEO; Dr. Suyash Prasad, Chief Medical Officer and Head of R&D; Dr. Frederick Porter, Chief Technical Officer; and Kamran Alam, Chief Financial Officer. After our formal remarks, we will conduct a question-and-answer session and instructions will follow at that time.
Earlier today, Taysha issued a press release announcing that we have entered into a strategic investment with Astellas Pharma to support the development of Taysha's AAV-based gene therapy
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |